3/25/2020 | SP | New Issue: Credit Suisse $585,000 contingent coupon autocallable yield notes on three stocks
|
3/2/2020 | SP | Credit Suisse eyes contingent coupon autocalls tied to three stocks
|
8/15/2019 | SP | New Issue: Credit Suisse $1.37 million contingent coupon autocallable yield notes on three stocks
|
8/15/2019 | SP | New Issue: Credit Suisse $1.18 million contingent coupon autocallable yield notes on three stocks
|
8/5/2019 | SP | Credit Suisse plans contingent coupon autocallable yield notes on stocks
|
6/7/2018 | SP | New Issue: Credit Suisse prices $1 million reverse convertibles linked to Nektar Therapeutics
|
10/6/2015 | HYIG | Market Commentary: Nektar places $250 million 7.75% notes; STAG, AllianzGI, WashingtonFirst announce issues
|
10/6/2015 | PV | New Issue: Nektar Therapeutics places $250 million of five-year notes with TPG Special Situations
|
10/6/2015 | HYLM | Nektar Therapeutics redeems in full $125 million 12% notes due 2017
|
8/9/2012 | CVLM | Nektar Therapeutics repurchased $42.5 million of convertibles July 11
|
7/10/2012 | HY | New Issue: Nektar Therapeutics prices $125 million five-year notes at par to yield 12%
|
7/9/2012 | HY | Market Commentary: Upsized Community Health, B/E Aerospace, Icahn deals price; ATP, Pilgrims Pride slide
|
1/18/2011 | CVHYPF | Nektar Therapeutics files automatic shelf for stock, debt, preferreds
|
7/27/2010 | CV | Market Commentary: Gilead opens higher, comes in; Onyx, ViroPharma in trade; AGCO in line; A&P bounces around
|
3/5/2010 | CV | Market Commentary: Priceline trades to 101 on debut; Nektar extends gains; SandDisk retraces gains; AMD rises
|
3/3/2010 | CV | Market Commentary: Analyst support helps Nektar, SanDisk; Massey up with rumors; Micron, NII firm; Vedanta upsizes
|
9/23/2009 | CV | Market Commentary: AMR, Goodrich Petroleum gain on debuts; Gaylord Entertainment, PHH price upsized deals
|
9/21/2009 | CV | Market Commentary: AMR launches convertible; Amgen, MannKind, Nektar active in trade; Sonic, Kodak richen
|
11/6/2008 | CV | Nektar Therapeutics buys back $100 million in convertible debt
|
4/9/2008 | CV | Market Commentary: Convertibles mostly softer; Citigroup, WaMu ease; Exubera news hits Nektar; Virgin, Endo to price
|
10/18/2007 | CV | Market Commentary: CIT active but stays still; Medtronic continues slide; St. Jude down; Nektar tumbles as Pfizer pulls drug
|
11/7/2006 | BT | Nektar driving toward profitability with planned Exubera launch, proprietary advancements
|
11/3/2006 | BT | Merrill reiterates Netkar at buy
|
10/26/2006 | BT | Merrill puts Netkar at buy
|
10/19/2006 | BT | Merrill puts Nektar at buy
|
9/21/2006 | BT | Nektar, Zelos to study inhaled Ostabolin-C for osteoporosis
|
9/18/2006 | BT | Market Commentary: Genentech steady on Glaxo filing; Cell Therapeutics, Inovio gain on deals; MannKind up, Nektar down
|
8/4/2006 | BT | Merrill gives Nektar a buy rating
|
8/2/2006 | BT | Nektar kept at buy by Merrill
|
7/28/2006 | BT | Merrill puts Nektar at buy
|
7/27/2006 | BT | Nektar at buy from Merrill
|
7/24/2006 | BT | Nektar receives $17.6 million milestone payment from Affymax
|
7/21/2006 | BT | Market Commentary: Amgen stronger; ReGen cheered; Cleveland BioLabs debuts lower; Amylin, Nektar weaker
|
7/20/2006 | BT | Market Commentary: Amgen weakens; Gilead off 3%; Alfacell falls 30%; Nektar up; Accentia lower; Connetics lifted
|
7/20/2006 | BT | Nektar gets buy rating from Merrill
|
7/7/2006 | BT | Nektar, University of Alabama to settle litigation for $25 million
|
7/7/2006 | BT | Market Commentary: LifeCell lower; CV Therapeutics loses 2%; Indevus up; Tercica off by 8%; Amarillo Biosciences off
|
6/29/2006 | BT | Alexion kept at buy by Merrill
|
6/13/2006 | CV | Market Commentary: Advanced Medical, Charles River, Nabors gain on volatility; Symantec flat on debut; Nektar drops outright
|
5/22/2006 | BT | FDA grants fast track designation to Nektar's Amphotericin B Inhalation Powder
|
5/22/2006 | BT | Market Commentary: Adventrx gains after pulling deal; Dyax gains, Icos slips on pact; Cell Therapeutics declines 7%
|
5/11/2006 | BT | Nektar at buy from Merrill
|
5/1/2006 | BT | Merrill keeps Nektar at buy
|
4/19/2006 | BT | Market Commentary: Genzyme crashes on miss; Nektar dips, ends higher; MannKind off; Icon better; Nabi adds another 4%
|
4/19/2006 | BT | Merrill holds Nektar at buy
|
3/1/2006 | BT | Merrill rates Nektar at buy
|
3/1/2006 | BT | Market Commentary: Cepheid follow-on on deck; Akorn bags $19.4 million; Novavax results priced in; Exubera buoys Nektar
|
3/1/2006 | CV | Market Commentary: HealthSouth, ArvinMeritor deals get warm reception; Woodson says convertibles making comeback
|
2/23/2006 | BT | Merrill keeps Nektar at buy
|
2/14/2006 | BT | Market Commentary: Amgen rejigs deal, still a magnet to convertibles, stock players; Chelsea, YM taps PIPEs; Nektar breaks out
|
2/14/2006 | BT | Nektar gets orphan drug designation for inhalation powder for pulmonary fungal infections
|
2/10/2006 | BT | Market Commentary: Acorda shares close up 12%; Shire better, other ADHD names off on drug labeling; Pfizer slides
|
2/10/2006 | CV | Market Commentary: Freeport-McMoran, Inco sink in metals meltdown; Level 3 gains while investors still sweet on Nektar
|
2/8/2006 | CV | Market Commentary: Citadel retraces some gains; Qwest flat but adds on hedge; MGI better; Oil States lower; Pier 1 prices
|
1/30/2006 | CV | Market Commentary: Omnicare converts plunge on raid news; new DRS issue slows down; GMAC bids lift GM
|
1/30/2006 | CV | Market Commentary: Omnicare converts plunge on raid news; new DRS issue slows down; GMAC bids lift GM
|
1/30/2006 | BT | Merrill keeps Nektar at buy
|
1/30/2006 | BT | Market Commentary: Theravance at bat; Amylin dives; Nektar reverses; CV Therapeutics takes a hit; First Horizon higher
|
1/27/2006 | BT | Market Commentary: Arena up after follow-on; Altus interest grows; Nektar, Pfizer up; Glaxo gains on Gates' TB pledge; Teva prices
|
1/27/2006 | BT | Market Commentary: Arena up after follow-on; Altus interest grows; Nektar, Pfizer up; Glaxo gains on Gates' TB pledge; Teva prices
|
1/27/2006 | CV | Market Commentary: Deals from Teva, AAR draw attention to new issues; Nektar in play on product rumors; GM up
|
1/26/2006 | BT | Merrill rates Nektar at buy
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/19/2006 | BT | Market Commentary: Endo Pharmaceuticals prices $417.75 million secondary stock sale; Procyon to merge with Cellpep
|
1/19/2006 | CV | Market Commentary: Advanced Micro, Cypress gain, but Intel weaker; Hutchinson prices upsized $225 million deal
|
1/13/2006 | BT | Merrill maintains Nektar at buy
|
1/13/2006 | BT | Market Commentary: Nektar up over 10% on Pfizer's move; Encysive, Alexion up big; Biopure loses 4% after follow-on
|
1/11/2006 | BT | Merrill maintains Nektar at buy
|
1/9/2006 | BT | Market Commentary: Human Genome, Amgen higher on license pact; Alnylam soars on 2006 view; NPS, Oscient up big
|
1/5/2006 | BT | Market Commentary: Advancis sale of Keflex stumbles; Nuvelo spikes on Bayer pact; buyers snap up Nektar, MannKind
|
11/22/2005 | CV | Market Commentary: Convertible market mostly higher; Calpine drops on court decision; GM extends losses
|
11/21/2005 | CV | Market Commentary: GM mixed in light trade, Ford flat, Incyte gains on Pfizer pact, but SFBC falls
|
11/16/2005 | CV | Market Commentary: Convertible market finds a foothold, but GM, Ford resume slide; EDO reoffered at 99
|
11/14/2005 | CV | Market Commentary: Convertibles market weaker, including GM, Micron Technology; EDO, The Pantry launch offers
|
11/4/2005 | CV | Market Commentary: Qwest, Chesapeake remain active; Celgene up, Emdeon lower; King sideways
|
11/4/2005 | BT | Merrill Lynch keeps Nektar's buy rating
|
11/4/2005 | BT | Market Commentary: Introgen's stock lifts on Colgate-Palmolive alliance; Cytori, Olympus enter into joint venture
|
10/28/2005 | BT | Merrill Lynch maintains Nektar at buy
|
10/28/2005 | CV | Market Commentary: Invitrogen drops, but gains on hedge; Amkor steadies after fall; Nektar weaker
|
10/21/2005 | CV | Market Commentary: Wyeth holds up; Ford drops, but GM bonds move higher; Schlumberger off
|
10/20/2005 | CV | Market Commentary: Convertibles market reverses course after strong start; Cypress pulled down; Amgen, biotechs weaker
|
10/13/2005 | BT | Nektar receives buy rating from Merrill
|
10/13/2005 | CV | Market Commentary: Late rally lifts GM bonds, default swaps; energy drops, but Devon/Chevron bonds better; Nektar gains
|
9/30/2005 | BT | Nektar price target lowered by Merrill
|
9/30/2005 | CV | Market Commentary: Micron trades actively on profit news; Interpublic, Northwest add; Trizetto reoffered at 98
|
9/27/2005 | CV | Market Commentary: US Airways' convertible deal eyed; Nektar extends gains; but selling weighs on overall market
|
9/27/2005 | BTCV | Nektar greenshoe fully exercised, augmenting 3.25% convertibles offer to $315 million
|
9/26/2005 | CV | Market Commentary: Dick's Sporting Goods, Best Buy trade; airlines lower; General Mills' put looks likely to entice holders
|
9/23/2005 | BT | Market Commentary: Nektar upsizes home-run convertible, Renovis raves, Acusphere sinks after follow-ons; Cyberonics slips
|
9/23/2005 | CV | Market Commentary: Nektar moves up in robust trade; energy eases; airlines lift; Rite Aid stays firm
|
9/23/2005 | BTCV | New Issue: Nektar sells upsized $275 million seven-year convertibles to yield 3.25%, up 32.5%
|
9/22/2005 | CV | Market Commentary: Citi/Genworth SYNdecs close flat; Wesco, Toreador gain, but Cyberonics drops; Nektar eyed
|
9/22/2005 | BT | Market Commentary: Nektar convertible at bat along with follow-ons from GTx, Renovis; Cyberonics prices wide, closes off
|
9/21/2005 | CV | Market Commentary: Chesapeake, Devon/Chevron trade; Chiron down; Nektar launches deal; Citi/Genworth prices
|
9/21/2005 | CV | Nektar Therapeutics to buy back convertibles with new offering proceeds
|
9/21/2005 | BTCV | Nektar $200 million seven-year convertibles talked to yield 3.25%-3.75%, up 27.50%-32.50%
|
9/12/2005 | BTPP | New Issue: Nektar Therapeutics releases details on $8 million direct placement
|
9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
9/9/2005 | BT | Nektar maintained by Merrill Lynch at buy
|
9/8/2005 | BT | Market Commentary: Myogen, NPS float follow-ons; Nektar halted during FDA panel; Sepracor up in face of generic filing
|
9/8/2005 | CV | Market Commentary: Convertibles trade mixed, with Amgen, Nabors edging up, Cypress Semiconductor down
|
9/8/2005 | BTPP | Nektar sells $8 million of stock as Mansfield exercises option
|
9/7/2005 | BT | Market Commentary: ID Biomedical climbs 13% on Glaxo acquisition; Chiron still rising; Nektar zooms over 10%
|
8/31/2005 | BT | Nektar maintained by Merrill at buy
|
8/17/2005 | PP | Market Commentary: PIPE volume holds steady as stocks rebound; Global Alumina raises $100 million
|
8/16/2005 | BT | Market Commentary: Kosan retreats further after pulling follow-on; Nektar slips; Acambis off, Electro-Optical IPO seen delayed
|
8/16/2005 | PP | Market Commentary: Slacking stocks stave off new PIPE deals; Nektar Therapeutics raises $24 million in direct placement
|
8/16/2005 | BTPP | New Issue: Nektar Therapeutics raises $24 million from stock offering
|
8/15/2005 | BT | Nektar to acquire Aerogen for $32 million
|
8/15/2005 | BT | Nektar Therapeutics kept at buy by Merrill
|
8/5/2005 | BT | Nektar maintained by Merrill at buy
|
7/26/2005 | BT | Nektar reiterated by Merrill at buy
|
7/22/2005 | BT | Nektar maintained by Merrill Lynch at buy
|
7/19/2005 | BT | Nektar initiated by Global Crown at underweight
|
10/27/2004 | CVHY | Nektar files $250 million shelf
|
6/8/2004 | CV | Market Commentary: Players taking a reality check in wake of Mandalay upset find the market discounted considerably
|
4/1/2004 | CV | Nektar calls 63/4% convertibles
|
3/30/2004 | CV | Nektar says all 3% convertibles exchanged for stock ahead of redemption
|
3/8/2004 | CV | Nektar Therapeutics calls 3% convertibles
|
1/26/2004 | CV | Nektar exchanges $9 million 3.5% convertibles for stock
|
11/3/2003 | CV | Nektar issues $11.71 million 3% convertibles in exchange for $17.125 million 3.5% convertibles
|
10/20/2003 | CV | Nektar issues $13.978 million 3% convertibles in exchange for $20.815 million 3.5% convertibles
|
10/10/2003 | CV | Nektar issues $33.6 million 3% convertibles in exchange for $50 million 3.5% convertibles
|
8/28/2003 | CV | Market Commentary: Miscellaneous scraps of convertible paper trading; action to heat up next week
|
7/30/2003 | CV | Nektar greenshoe exercised, raising convertibles to $110 million, buys back $20.5 million old convertibles
|
6/25/2003 | CV | New Issue: Nektar sells $100 million convertible at 3.0% yield, up 29.7%
|
6/25/2003 | CV | Market Commentary: Halliburton, EDS shoot up after pricing; yield-seekers on the hunt in wake of Fed ease
|
6/24/2003 | CV | Market Commentary: Demand squeeze forces new deals to wide end of ranges; Nektar sweetens
|
6/23/2003 | CV | Nektar $100 million convertibles talked to yield 1.75-2.25%, up 25-30%
|
6/23/2003 | CV | Market Commentary: Market cheapening poses double-edged sword as new paper suffers; 4 deals emerge
|
1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|